Difference between revisions of "Glycoprotein non-metastatic B"

From Libre Pathology
Jump to navigation Jump to search
(Created page with "'''Glycoprotein non-metastatic B''', abbreviated '''GPNMB''', is an immunostain. It is typically positive in TSC1/TSC2/MTOR mutated renal cell carcinomas.<ref name=pmid37...")
 
(carete)
Line 3: Line 3:
It is typically positive in TSC1/TSC2/MTOR mutated renal cell carcinomas.<ref name=pmid37661807>{{cite journal |authors=Li H, Argani P, Halper-Stromberg E, Lotan TL, Merino MJ, Reuter VE, Matoso A |title=Positive GPNMB Immunostaining Differentiates Renal Cell Carcinoma With Fibromyomatous Stroma Associated With TSC1/2/MTOR Alterations From Others |journal=Am J Surg Pathol |volume=47 |issue=11 |pages=1267–1273 |date=November 2023 |pmid=37661807 |doi=10.1097/PAS.0000000000002117 |url=}}</ref>
It is typically positive in TSC1/TSC2/MTOR mutated renal cell carcinomas.<ref name=pmid37661807>{{cite journal |authors=Li H, Argani P, Halper-Stromberg E, Lotan TL, Merino MJ, Reuter VE, Matoso A |title=Positive GPNMB Immunostaining Differentiates Renal Cell Carcinoma With Fibromyomatous Stroma Associated With TSC1/2/MTOR Alterations From Others |journal=Am J Surg Pathol |volume=47 |issue=11 |pages=1267–1273 |date=November 2023 |pmid=37661807 |doi=10.1097/PAS.0000000000002117 |url=}}</ref>


==Positive==
*[[Angiomyolipoma]].
*[[TFE3-rearranged renal cell carcinoma]].
*[[TFEB-rearranged renal cell carcinoma]].
*[[Low-grade oncocytic tumour]] (LOT).
*[[PEComa]].
*[[RCC with FMS]].


==References==
==References==

Revision as of 13:27, 26 March 2024

Glycoprotein non-metastatic B, abbreviated GPNMB, is an immunostain.

It is typically positive in TSC1/TSC2/MTOR mutated renal cell carcinomas.[1]


Positive

References

  1. Li H, Argani P, Halper-Stromberg E, Lotan TL, Merino MJ, Reuter VE, Matoso A (November 2023). "Positive GPNMB Immunostaining Differentiates Renal Cell Carcinoma With Fibromyomatous Stroma Associated With TSC1/2/MTOR Alterations From Others". Am J Surg Pathol 47 (11): 1267–1273. doi:10.1097/PAS.0000000000002117. PMID 37661807.